ClinicalTrials.gg
CompletedNCT01994720SOCRATESUpdated Jun 12, 2017Results posted

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

A Phase 3 interventional study of ticagrelor and Acetylsalicylic acid (ASA) in Acute Ischaemic Stroke and Transient Ischaemic Attack, sponsored by AstraZeneca. Completed at 528 sites in 33 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2017-06-12.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13,307
Allocation
Randomized
Ages
40 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Ischemic Attack, Transient with a site in United States — 10 open to participants now, 14 under way, 1 of them phase 3. Ischemic Attack, Transient · United States.

Enrollment
Largest of 65
13,307 · median 202
Started
2014
with 3 others
Phase 3
12 of 88
1 open now
Registered
48th of 88
by date
Lead sponsor
2 of 88
AstraZeneca

Among the 88 studies in Ischemic Attack, Transient with a site in United States, this one has the largest enrollment of the 65 interventional ones that give a count, is one of 4 that started in 2014, is one of 12 in phase 3, and was the 48th registered.

Ischemic Attack, Transient

329 studies on the registry are indexed under Ischemic Attack, Transient; 71 are open to participants now.

Browse Ischemic Attack, Transient studies →

Open to participants now

10 of the 88 studies in Ischemic Attack, Transient with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Ischemic Attack, Transient studies recruiting now, 36 (67%) set no upper age limit and 6 (11%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.

This study: 40 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Ischemic Attack, Transient with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs acetylsalicylic acid (ASA)-aspirin (300 mg [three 100 mg tablets] loading dose on Day 1 followed by 100 mg once daily maintenance dose for the remainder of the study) for the prevention of major vascular events (composite of stroke, myocardial infarction [MI], and death) in patients with acute ischaemic stroke or transient ischaemic attack (TIA).

03

Conditions studied

  • Acute Ischaemic Stroke
  • Transient Ischaemic Attack

Keywords

  • Acute ischaemic stroke.
  • Transient ischaemic attack.
04

Who can participate

Ages eligible
40 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Men or women equal or elder 40 years of age
  • Either acute ischaemic stroke or high-risk as defined here and randomisation occurring within 24 hours after onset of symptoms

Key Exclusion Criteria:

  • Planned use of antithrombotic therapy in addition to study medication including antiplatelets (eg, open label ASA, GPIIb/IIIa inhibitors, clopidogrel, ticlopidine, prasugrel, dipyridamole, ozagrel, cilostazol) and anticoagulants (eg, warfarin, oral thrombin and factor Xa inhibitors, bivalirudin, hirudin, argatroban, unfractionated and low molecular weight heparins). - Any history of atrial fibrillation, ventricular aneurysm or suspicion of cardioembolic pathology for TIA or stroke. - Planned carotid, cerebrovascular, or coronary revascularisation that requires halting study medication within 7 days of randomisation. - Receipt of any intravenous or intra-arterial thrombolysis or mechanical thrombectomy within 24 hours prior to randomisation - History of previous symptomatic non-traumatic intracerebral bleed at any time (asymptomatic microbleeds do not qualify), gastrointestinal (GI) bleed within the past 6 months, or major surgery within 30 days.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
13,307 participants (actual)

Study arms

  • Experimental
    ticagrelor

    Drug: ticagrelor

  • Active comparator
    Acetylsalicylic acid (ASA)

    Drug: Acetylsalicylic acid (ASA)

Interventions

  • ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.

  • ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Composite of Stroke/MI/Death

    Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97).

    Time frame: From randomization up to 97 days

Secondary outcomes

  1. Number of Participants With Ischaemic Stroke

    Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).

    Time frame: From randomization up to 97 days

  2. Net Clinical Outcome

    Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97).

    Time frame: From randomization up to 97 days

  3. Number of Participants With Composite of Ischaemic Stroke, MI and CV Death

    Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).

    Time frame: From randomization up to 97 days

  4. Number of Participants With All-Cause Death

    Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97).

    Time frame: From randomization up to 97 days

  5. Number of Participants With CV Death

    Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).

    Time frame: From randomization up to 97 days

  6. Number of Participants With MI

    Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97)

    Time frame: From randomization up to 97 days

  7. Number of Participants by Severity of Stroke and Overall Disability

    Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS. Modified Rankin Score: 0 - No symptoms. 1. - No significant disability. Able to carry out all usual activities, despite some symptoms. 2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. - Moderate disability. Requires some help, but able to walk unassisted. 4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. - Dead. Disability defined as mRS \> 1. Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables.

    Time frame: From randomization up to 97 days

  8. Number of Participants With Stroke

    Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97)

    Time frame: From randomization up to 97 days

  9. Number of Participants With Fatal Stroke

    Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).

    Time frame: From randomization up to 97 days

  10. Number of Participants With Disabling Stroke

    Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).

    Time frame: From randomization up to 97 days

  11. Change in NIHSS

    Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale): 0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke.

    Time frame: From randomization up to 97 days

  12. EQ-5D at Visit 1 (Enrolment)

    EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.

    Time frame: Visit 1 (Enrolment)

  13. EQ-5D at Visit 2 (Day 7+-2d)

    EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.

    Time frame: Visit 2 (Day 7+-2d)

  14. EQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit

    EQ-5D index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.

    Time frame: End of treatment visit (Day 90+-7d)

  15. EQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit

    EQ-5D index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.

    Time frame: Premature treatment discontinuation visit(<15 days after last dose)

  16. Number of Participants With PLATO Major Bleeding Event

    Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). PLATO Major bleeding is defined as a bleed that is any one of: * Fatal * Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages \<10 mm evident only on gradient-echo MRI) * Intrapericardial bleed with cardiac tamponade * Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery * Significantly disabling (eg. intraocular with permanent vision loss) * Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L) * Transfusion of 2 or more units (whole blood or packed red blood cells \[PRBCs\]) for bleeding.

    Time frame: From randomization up to 97 days

  17. Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event

    Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).

    Time frame: Time from first dose and up to and including 7 days following the date of last dose of the study

07

Results

Posted Jun 12, 2017

Participant flow

In total, 13307 patients were enrolled from 674 study sites in 33 countries. The first patient was enrolled on 07 January 2014. The last patient visit took place on 02 March 2016.

Participant flow — Overall Study
MilestoneTicagrelor 90 mgASA 100 mg
Started65896610
Completed65436554
Not completed4656
Withdrew: Withdrawal by subject4656

Outcome measures

PrimaryNumber of Participants With Composite of Stroke/MI/Death

Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97).

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Number of Participants With Composite of Stroke/MI/Death
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants With Composite of Stroke/MI/Death442497
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = 0.0670 (In order to address the issue of multiple testing, a hierarchical test sequence will be used. Tested at 4.98% level.) · Hazard ratio (hr): 0.89 · 95% CI 0.78 to 1.01
SecondaryNumber of Participants With Ischaemic Stroke

Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Number of Participants With Ischaemic Stroke
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants With Ischaemic Stroke385441
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = 0.0462 (If the treatment effect on the primary efficacy variable is significant at the 4.98% level, the secondary efficacy variable will be tested in a confirmatory sense. Otherwise it will be tested in an exploratory manner.) · Hazard ratio (hr): 0.87 · 95% CI 0.76 to 1.00
SecondaryNet Clinical Outcome

Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97).

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Net Clinical Outcome
ParticipantsTicagrelor 90 mgASA 100 mg
Net Clinical Outcome457508
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = 0.0928 · Hazard ratio (hr): 0.90 · 95% CI 0.79 to 1.02
SecondaryNumber of Participants With Composite of Ischaemic Stroke, MI and CV Death

Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Number of Participants With Composite of Ischaemic Stroke, MI and CV Death
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants With Composite of Ischaemic Stroke, MI and CV Death423475
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = 0.0771 · Hazard ratio (hr): 0.89 · 95% CI 0.78 to 1.01
SecondaryNumber of Participants With All-Cause Death

Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97).

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Number of Participants With All-Cause Death
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants With All-Cause Death6858
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = 0.3641 · Hazard ratio (hr): 1.18 · 95% CI 0.83 to 1.67
SecondaryNumber of Participants With CV Death

Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Number of Participants With CV Death
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants With CV Death4135
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = 0.4828 · Hazard ratio (hr): 1.18 · 95% CI 0.75 to 1.85
SecondaryNumber of Participants With MI

Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97)

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Number of Participants With MI
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants With MI2521
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = 0.5457 · Hazard ratio (hr): 1.20 · 95% CI 0.67 to 2.14
SecondaryNumber of Participants by Severity of Stroke and Overall Disability

Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS. Modified Rankin Score: 0 - No symptoms. 1. - No significant disability. Able to carry out all usual activities, despite some symptoms. 2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. - Moderate disability. Requires some help, but able to walk unassisted. 4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. - Dead. Disability defined as mRS \> 1. Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables.

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Number of Participants by Severity of Stroke and Overall Disability
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants by Severity of Stroke and Overall Disability11071194
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Logistic · p = 0.1393 · Odds ratio (or): 0.93 · 95% CI 0.85 to 1.02
SecondaryNumber of Participants With Stroke

Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97)

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Number of Participants With Stroke
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants With Stroke390450
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = 0.0342 · Hazard ratio (hr): 0.86 · 95% CI 0.75 to 0.99
SecondaryNumber of Participants With Fatal Stroke

Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Number of Participants With Fatal Stroke
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants With Fatal Stroke1817
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = 0.8557 · Hazard ratio (hr): 1.06 · 95% CI 0.55 to 2.06
SecondaryNumber of Participants With Disabling Stroke

Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Number of Participants With Disabling Stroke
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants With Disabling Stroke277307
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = 0.2126 · Hazard ratio (hr): 0.90 · 95% CI 0.77 to 1.06
SecondaryChange in NIHSS

Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale): 0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke.

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Change in NIHSS
ParticipantsTicagrelor 90 mgASA 100 mg
<=-5132127
-4403438
-3779810
-210881073
-110991131
0681683
16779
22831
31816
41311
566
>51014
Missing474450
SecondaryEQ-5D at Visit 1 (Enrolment)

EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.

Time frame:
Visit 1 (Enrolment)
Reported as:
Mean · Index score
EQ-5D at Visit 1 (Enrolment)
Index scoreTicagrelor 90 mgASA 100 mg
EQ-5D at Visit 1 (Enrolment)0.70 ± 0.2970.70 ± 0.298
SecondaryEQ-5D at Visit 2 (Day 7+-2d)

EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.

Time frame:
Visit 2 (Day 7+-2d)
Reported as:
Mean · Index score
EQ-5D at Visit 2 (Day 7+-2d)
Index scoreTicagrelor 90 mgASA 100 mg
EQ-5D at Visit 2 (Day 7+-2d)0.80 ± 0.2440.79 ± 0.262
SecondaryEQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit

EQ-5D index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.

Time frame:
End of treatment visit (Day 90+-7d)
Reported as:
Mean · Index score
EQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit
Index scoreTicagrelor 90 mgASA 100 mg
EQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit0.85 ± 0.2030.84 ± 0.208
SecondaryEQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit

EQ-5D index score using the UK tariff. EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples. The higher the index score the better the health state. In this study index scores ran from -0.59 to 1.

Time frame:
Premature treatment discontinuation visit(<15 days after last dose)
Reported as:
Mean · Index score
EQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit
Index scoreTicagrelor 90 mgASA 100 mg
EQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit0.72 ± 0.3300.68 ± 0.364
SecondaryNumber of Participants With PLATO Major Bleeding Event

Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). PLATO Major bleeding is defined as a bleed that is any one of: * Fatal * Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages \<10 mm evident only on gradient-echo MRI) * Intrapericardial bleed with cardiac tamponade * Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery * Significantly disabling (eg. intraocular with permanent vision loss) * Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L) * Transfusion of 2 or more units (whole blood or packed red blood cells \[PRBCs\]) for bleeding.

Time frame:
From randomization up to 97 days
Reported as:
Number · Participants
Number of Participants With PLATO Major Bleeding Event
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants With PLATO Major Bleeding Event3138
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = 0.4511 · Hazard ratio (hr): 0.83 · 95% CI 0.52 to 1.34
SecondaryNumber of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event

Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).

Time frame:
Time from first dose and up to and including 7 days following the date of last dose of the study
Reported as:
Number · Participants
Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event
ParticipantsTicagrelor 90 mgASA 100 mg
Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event8237
Statistical analysis
  • Ticagrelor 90 mg vs ASA 100 mg · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 2.26 · 95% CI 1.53 to 3.34

Adverse events

Collected over On or after the date of first dose and up to and including 7 days following the date of last dose of study medication. 97 days if the participant completed treatment according to the study plan.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ASA 100mg—533/6,581 (8.1%)85/6,581 (1.3%)
Ticagrelor 90mg—532/6,549 (8.1%)383/6,549 (5.8%)
Most frequent serious events
Showing 10 of 449
Most frequent serious events
EventASA 100mgTicagrelor 90mg
Transient ischaemic attackNervous system disorders68/658155/6549
Carotid artery stenosisNervous system disorders27/658128/6549
Atrial fibrillationCardiac disorders21/658124/6549
PneumoniaInfections and infestations23/658119/6549
HypertensionVascular disorders11/658112/6549
Angina unstableCardiac disorders4/658111/6549
DyspnoeaRespiratory, thoracic and mediastinal disorders1/658111/6549
Pulmonary embolismRespiratory, thoracic and mediastinal disorders10/65814/6549
Urinary tract infectionInfections and infestations4/65818/6549
Cardiac failureCardiac disorders7/65817/6549
Most frequent other events
Most frequent other events
EventASA 100mgTicagrelor 90mg
DyspnoeaRespiratory, thoracic and mediastinal disorders85/6581383/6549

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ticagrelor 90 mgASA 100 mgTotal
Mean65.8 ± 11.2365.9 ± 11.3765.9 ± 11.30
Age, Customized
Age, Customized(Participants)Ticagrelor 90 mgASA 100 mgTotal
<65 years302130076028
Between 65 and 75 years206421124176
>75 years150414912995
Sex: Female, Male
Sex: Female, Male(Participants)Ticagrelor 90 mgASA 100 mgTotal
Female275927245483
Male383038867716
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ticagrelor 90 mgASA 100 mgTotal
Hispanic or Latino5665581124
Not Hispanic or Latino6023605012073
Unknown or Not Reported022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticagrelor 90 mgASA 100 mgTotal
American Indian or Alaska Native6974143
Asian195719493906
Native Hawaiian or Other Pacific Islander415
Black or African American119120239
White437444108784
Other6656122
08

Study locations

528 sites
  • Research Site
    Montgomery, Alabama, United States
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    Fayetteville, Arkansas, United States
  • Research Site
    Fort Smith, Arkansas, United States
  • Research Site
    Fullerton, California, United States
  • Research Site
    Glendale, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Newport, California, United States
  • Research Site
    Oakland, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Stanford, California, United States
  • Research Site
    Torrance, California, United States
  • Research Site
    Englewood, Colorado, United States
  • Research Site
    Altamonte Springs, Florida, United States
  • Research Site
    Aventura, Florida, United States
  • Research Site
    Boynton Beach, Florida, United States
  • Research Site
    Bradenton, Florida, United States
  • Research Site
    Gainesville, Florida, United States
  • Research Site
    Hialeah, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Lakeland, Florida, United States
  • Research Site
    Melbourne, Florida, United States
  • Research Site
    Pompano Beach, Florida, United States
  • Research Site
    Port Charlotte, Florida, United States
  • Research Site
    Sarasota, Florida, United States
  • Research Site
    Tampa, Florida, United States
  • Research Site
    West Palm Beach, Florida, United States
  • Research Site
    Weston, Florida, United States
  • Research Site
    Columbus, Georgia, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Evanston, Illinois, United States
  • Research Site
    Glenview, Illinois, United States
  • Research Site
    Harvey, Illinois, United States
  • Research Site
    Joliet, Illinois, United States
  • Research Site
    Park Ridge, Illinois, United States
  • Research Site
    Springfield, Illinois, United States
  • Research Site
    Urbana, Illinois, United States
  • Research Site
    Anderson, Indiana, United States
  • Research Site
    Fort Wayne, Indiana, United States
  • Research Site
    Muncie, Indiana, United States
  • Research Site
    Des Moines, Iowa, United States
  • Research Site
    Iowa City, Iowa, United States
  • Research Site
    Alexandria, Louisiana, United States
  • Research Site
    New Orleans, Louisiana, United States
  • Research Site
    Annapolis, Maryland, United States
  • Research Site
    Frederick, Maryland, United States
  • Research Site
    Boston, Massachusetts, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    Pontiac, Michigan, United States
  • Research Site
    Royal Oak, Michigan, United States
  • Research Site
    Southfield, Michigan, United States
  • Research Site
    West Bloomfield Township, Michigan, United States
  • Research Site
    Minneapolis, Minnesota, United States
  • Research Site
    Robbinsdale, Minnesota, United States
  • Research Site
    Saint Paul, Minnesota, United States
  • Research Site
    Bridgeton, Missouri, United States
  • Research Site
    Columbia, Missouri, United States
  • Research Site
    Kansas City, Missouri, United States
  • Research Site
    Saint Louis, Missouri, United States
  • Research Site
    Great Falls, Montana, United States
  • Research Site
    Helena, Montana, United States
  • Research Site
    Omaha, Nebraska, United States
  • Research Site
    Lebanon, New Hampshire, United States
  • Research Site
    Bayonne, New Jersey, United States
  • Research Site
    Edison, New Jersey, United States
  • Research Site
    Englewood, New Jersey, United States
  • Research Site
    Flemington, New Jersey, United States
  • Research Site
    New Brunswick, New Jersey, United States
  • Research Site
    Ridgewood, New Jersey, United States
  • Research Site
    West Orange, New Jersey, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    Brooklyn, New York, United States
  • Research Site
    Buffalo, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Stony Brook, New York, United States
  • Research Site
    Syracuse, New York, United States
  • Research Site
    The Bronx, New York, United States
  • Research Site
    Chapel Hill, North Carolina, United States
  • Research Site
    Charlotte, North Carolina, United States
  • Research Site
    Durham, North Carolina, United States
  • Research Site
    Greensboro, North Carolina, United States
  • Research Site
    Winston-Salem, North Carolina, United States
  • Research Site
    Akron, Ohio, United States
  • Research Site
    Cleveland, Ohio, United States
  • Research Site
    Columbus, Ohio, United States
  • Research Site
    Maumee, Ohio, United States
  • Research Site
    Toledo, Ohio, United States
  • Research Site
    Clackamas, Oregon, United States
  • Research Site
    Portland, Oregon, United States
  • Research Site
    Abington, Pennsylvania, United States
  • Research Site
    Allentown, Pennsylvania, United States
  • Research Site
    Doylestown, Pennsylvania, United States
  • Research Site
    Erie, Pennsylvania, United States
  • Research Site
    Hershey, Pennsylvania, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Providence, Rhode Island, United States
  • Research Site
    Charleston, South Carolina, United States
  • Research Site
    Columbia, South Carolina, United States
  • Research Site
    Sioux Falls, South Dakota, United States
  • Research Site
    Chattanooga, Tennessee, United States

Showing the first 100 of 528 sites across 33 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Diener HC, Easton JD, Hart RG, Kasner S, Kamel H, Ntaios G. Review and update of the concept of embolic stroke of undetermined source. Nat Rev Neurol. 2022 Aug;18(8):455-465. doi: 10.1038/s41582-022-00663-4. Epub 2022 May 10. PubMed 35538232 ↗
  • Evans SR, Knutsson M, Amarenco P, Albers GW, Bath PM, Denison H, Ladenvall P, Jonasson J, Easton JD, Minematsu K, Molina CA, Wang Y, Wong KL, Johnston SC. Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial. Clin Trials. 2020 Dec;17(6):617-626. doi: 10.1177/1740774520941441. Epub 2020 Jul 15. PubMed 32666831 ↗
  • Cucchiara B, George DK, Kasner SE, Knutsson M, Denison H, Ladenvall P, Amarenco P, Johnston SC. Disability after minor stroke and TIA: A secondary analysis of the SOCRATES trial. Neurology. 2019 Aug 13;93(7):e708-e716. doi: 10.1212/WNL.0000000000007936. Epub 2019 Jul 11. PubMed 31296654 ↗
  • Easton JD, Denison H, Evans SR, Knutsson M, Amarenco P, Albers GW, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KL, Johnston SC; SOCRATES Steering Committee and Investigators. Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. Int J Stroke. 2019 Dec;14(9):908-914. doi: 10.1177/1747493019851282. Epub 2019 May 15. PubMed 31092152 ↗
  • Molina CA, Johnston SC, Ladenvall P, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Knutsson M, Minematsu K, Rother J, Wang Y, Wong KSL; SOCRATES Steering Committee and Investigators. Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. Stroke. 2019 Mar;50(3):675-682. doi: 10.1161/STROKEAHA.118.022675. Erratum In: Stroke. 2019 Apr;50(4):e118. doi: 10.1161/STR.0000000000000186. PubMed 30776996 ↗
  • Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Himmelmann A, Kasner SE, Knutsson M, Ladenvall P, Minematsu K, Molina CA, Wang Y, Johnston SC; SOCRATES Steering Committee and Investigators. Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. Stroke. 2018 Jul;49(7):1678-1685. doi: 10.1161/STROKEAHA.118.020553. Epub 2018 Jun 18. PubMed 29915123 ↗
  • Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators. Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. Stroke. 2017 Sep;48(9):2480-2487. doi: 10.1161/STROKEAHA.117.017217. Epub 2017 Jul 18. PubMed 28720658 ↗
  • Easton JD, Aunes M, Albers GW, Amarenco P, Bokelund-Singh S, Denison H, Evans SR, Held P, Jahreskog M, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). Circulation. 2017 Sep 5;136(10):907-916. doi: 10.1161/CIRCULATIONAHA.117.028566. Epub 2017 Jun 27. PubMed 28655834 ↗
  • Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017 Apr;16(4):301-310. doi: 10.1016/S1474-4422(17)30038-8. Epub 2017 Feb 23. PubMed 28238711 ↗
  • Wang Y, Minematsu K, Wong KS, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Molina CA, Johnston SC; SOCRATES Steering Committee and Investigators. Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). Stroke. 2017 Jan;48(1):167-173. doi: 10.1161/STROKEAHA.116.014891. Epub 2016 Nov 29. PubMed 27899747 ↗
  • Held P, Himmelmann A, Ditmarsch M. Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program. Future Cardiol. 2016 Jul;12(4):405-18. doi: 10.2217/fca-2016-0028. Epub 2016 May 10. PubMed 27160944 ↗
  • Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS; SOCRATES Steering Committee and Investigators. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med. 2016 Jul 7;375(1):35-43. doi: 10.1056/NEJMoa1603060. Epub 2016 May 10. PubMed 27160892 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Mar 2016, 25 months.

Results were first posted in Jun 2017, 1 year 3 months after primary completion.

Of 13 phase 3 interventional studies under Ischemic Attack, Transient, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 51. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2013
First posted
Nov 26, 2013
StartActual
Jan 7, 2014
Primary completionActual
Mar 2, 2016
CompletionActual
Mar 2, 2016
Results first posted
Jun 12, 2017
Last update
Jun 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01994720
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 26, 2013
Start date
Jan 7, 2014
Primary completion
Mar 2, 2016
Completion
Mar 2, 2016
Results posted
Jun 12, 2017
Last update
Jun 12, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion